medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2025, Number 1

<< Back Next >>

Arch Med Urg Mex 2025; 17 (1)

The first factor is NOT forgotten: relevance of fibrinogen in the management of hemorrhagic shock

Ballesteros-Flores CG, Ballesteros-Rentería G, Terán-Flores H, Navarrete-Colin YA

Language: Spanish
References: 30
Page: 54-57
PDF size: 177.44 Kb.


ABSTRACT

Introduction: fibrinogen, also called Factor I. It is a dimeric plasma glycoprotein with globular/fibrous properties and a high molecular weight (340 kDa). In healthy adults, the plasma concentration is in the range of 2 to 4 g/L. Objective: Literature analysis on the main biochemical aspects of fibrinogen in trauma patients. Material and Methods: Review of the medical literature in English during the period 2022 to 2024. The most relevant scientific articles on fibrinogen and trauma were selected. Results: Fibrinogen is frequently decreased in patients who present a state of hemorrhagic shock. The critical fibrinogen level is ≤ 1 g/L. Therefore, it is recommended to maintain a plasma fibrinogen level ≥ 2 g/L. Conclusion: The present literature review demonstrates that patients with hemorrhagic shock will have a significant decrease in plasma fibrinogen.


REFERENCES

  1. Zhang Q, Zhou S, Zhou, J. Tigecycline Treatment Causes a Decreasein Fibrinogen Levels. Antimicrob. Agents Chemother. 2015;(59):1650-1655. DOI: 10.1128/AAC.04305-14.

  2. Pavord S, Maybury H. How I Treat Postpartum Hemorrhage. Blood2015;(125) 2759-2770. DOI: 10.1182/ blood-2014-10-512608.

  3. Inaba K, Karamanos E, Lustenberger T, et al. Impact of fibrinogenlevels on outcomes after acute injury in patients requiring a massivetransfusion. J Am Coll Surg. 2013;(216):290-7.

  4. O’Shaughnessy F, Atterbury C, Bolton Maggs. et al. Guidelines forthe use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.Br J Haematol. 2004;(126):11-28.

  5. Rourke C, Curry N, Khan S. et al. Fibrinogen Levels during TraumaHemorrhage, Response to Replacement Therapy, and Associationwith Patient Outcomes. J. Thromb. Haemost. 2022;(120):10-28.

  6. Spahn R, Bouillon B, Cerny V. et al. Management of bleedingand coagulopathy following major trauma: an updated Europeanguideline. Crit Care. 2013;(17):76.

  7. Cothren C, Moore E, Hedegaard B. et al. Epidemiology of urbantrauma deaths: a comprehensive reassessment 10 yeras later.World J Surg. 2007;(31):1507-11.

  8. Moore Hb, Moore EE. Temporal changes in fibrinolysis followinginjury. Semin Thromb Hemost. 2020;(46):189-191.

  9. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, WadaT, et al. Disseminated intravascular coagulation with a fibrinolyticphenotype at an early phase of trauma predicts mortality. ThrombRes. 2009;(124):608-13.

  10. Moore Hb, Moore EE, Gonzalez E. et al. Hiperfibrinolysis, physiologicfribrinolysis, and fribrinolysis shutdowm: The spectrum ofpostinjury fribrinolysis and relevance to antifibrinolytic therapy. JTrauma Acute Care. 2014;(77):811-817.

  11. Moore Hb, Moore EE, Liras IN. et al. Acute fribrinolysis shutdowmafter injury occurs frequently and increases mortality: A multicenterevaluation of 2,540 severely injured patients. J Am Coll Surg2016;(222):347-355.

  12. Simmons JW, Powel MF. Acute traumatic coagulopathy: Pathophysiologyand resuscitation. Br J Anaesth. 2016;(117):31-43.

  13. Hiippala ST, Myllyla GJ, Vhatera EM: Hemostatic factors and replacementof major blood loss with plasma-poorred cell concentrates.Anesth Analg. 1995;(81):360-365.

  14. Champion HR, Bellamy RF, Roberts CP, et al. A profile of combatinjury. J Trauma 2003;54(5)(suppl):S9-S13.

  15. Thomas D, Wee M, Clyburn P. et al. Association of Anaesthetistsof Great Britain and Ireland, Blood transfusion and the anaesthetist:management of massive haemorrhage. Anaesthesia.2010;(65):1153-1161.

  16. Hayakawa M, Gando S, Ono Y, Wada T, Yanagida Y, SawamuraA. Fibrinogen level deteriorates before other routine coagulationparameters and massive transfusion in the early phase of severetrauma: a retrospective observational study. Semin Thromb Hemost.2015;(41):35-42.

  17. Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation,fibrinolysis and inflammation. Thromb Haemost.2014;(112):649-658.

  18. López M, Martinuzzo M, Fares T, et al. Tromboelastometría ytromboelastografia. Acta Bioquímica Clínica Latinoamericana.2016;(50):319-328.

  19. McQuilten Z, Bailey M, Cameron, et al. Fibrinogen concentrationand use of fibrinogen supplementation with cryioprecipitate in patientswith critical bleeding receiving massive transfusión: A bi-nationalcohort study. Br J Haematol 2017;(179):131-141.

  20. Task Force on Patient Blood Management for Adult Cardiac Surgeryof the European Association for Cardio-thoracic Surgery (EACTS)and the European Association of Cardiothoracic AnesthesiologyEACTA, Boer C, Meesters MI. et al. 2017 EACTS/EACTA Guidelineson patient blood management for adult cardiac surgery. Journalof Cardiothoracic and Vascular Anesthesia. 2018;(32):88-120.

  21. Jensen H, Stensballe J, Afshari A. Comparing efficacy and safetyof fibrinogen concentrate to cryoprecipitate in bleeding patients:a systematic review. Acta Anaesthesiologica Scandinavica.2016;(60):1033-42.

  22. Koji Y, Akihiko U and Junki T. Fibrinogen concéntrate administrationattributes to significant reductions of blood loss and transfusiónrequirements in thoracic aortic repair. Journal of CardiothoracicSurgery. 2014;9:90.

  23. Taylor J, Cotton B. Problemas de coagulación en el paciente traumatizado.En: cameron J editor. Terapias quirúrgicas actuales.13ed. España; Elsevier. 2021:1251-1259.

  24. James Winearls and colls. Fibrinon Early In Severe Trauma study(FEISTY) results from an Australian multicentre randomised controlledpilot trial. Critical care and resucitation. 2021:(23).

  25. Cannon W. Hemorrhagic Shock. The New England Journal Of Medicine.2018;378(4):370-379.

  26. Winearls J, Reade MC, McQuilten Z, et al. Fibrinogen in traumatichaemorrhage. Curr Opin Anaesthesiol 2021;(34):514–520.

  27. Alexander J, Vlaar C, Sanne de Bruin, Marije Wijnberge S. JorindeRaasveld, et al. Transfusion strategies in bleeding critically ill adults:a clinical practice guideline from the European Society of IntensiveCare Medicine. Intensive Care Med. 2021;(47):1368-1392.

  28. Schlimp C and Schochl H. The role of fibrinogen in trauma-inducedcoagulopathy. Hamostaseologie. 2014;34(1):29-39.

  29. Ross J, Curry N, Cole E, et al. Effect or early empirical high-dosecryoprecipitate therapy on survival in major traumatic hemorrhage(CRYOSTAT-2);A randomized controlled trial. JAMA 2023.330(14):1315-1325.

  30. Wikkelsoe A, J Afshari, A.,Stensballe et al. The FIB-PPH trial: Fibrinogenconcentrate as initial treatment for postpartum heamorrhage:study protocol for a randomized controlled trial. Trials.2012;(2):92-110.




2020     |     www.medigraphic.com